Green Cross, COVID-19 (Plasma Therapy/Plasma Therapeutics) Theme Rises 6.85%

On the 29th, the COVID-19 (plasma treatment/plasma therapeutics) theme showed strength by rising 3.02% compared to the previous day, with Green Cross Corporation, a related stock, soaring 6.85%. Green Cross is known as a pharmaceutical company specializing in blood products and vaccines.

[Graph] Major stock price changes in the COVID-19 (plasma treatment/plasma therapeutics) theme

According to provisional data compiled at 14:26, foreign investors sold off -33,100 shares of Green Cross, indicating a large net selling by foreigners.

[Table] Net trading volume by foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Green Cross's quant financial score was 28.77 points, ranking 5th in the COVID-19 (plasma treatment/plasma therapeutics) related theme. This can be interpreted as Green Cross having relatively low investment attractiveness from a financial perspective. On the other hand, SMAC ranked first in quant financial score with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.